{"links":{"feed":"https://www.erudio.com/reports/trofuse-005-nct06132958/feed.json","html":"https://www.erudio.com/reports/trofuse-005-nct06132958","json":"https://www.erudio.com/reports/trofuse-005-nct06132958.json","markdown":"https://www.erudio.com/reports/trofuse-005-nct06132958.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"trofuse-005-nct06132958"}},"request":"https://www.erudio.com/contact?report=trofuse-005-nct06132958"},"offer":{"cited_clinicians":22,"cited_commentary_sources":70,"verified_hcp_statements":222,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":26},"for_sale":true,"one_off_usd":1250,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"trofuse-005-nct06132958"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=trofuse-005-nct06132958","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/trofuse-005-nct06132958","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"standard","size_line":"Standard · 222 verified statements · 66 from 22 confirmed clinicians","size_rule":"Standard: 151–300 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":2200,"6_months":3100,"12_months":4400},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-12T03:56:03.142876Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: the question clinicians left open; per-finding counts; the limitations; the examples from the report; the abstract, which no longer repeats the open question; the report description."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":0},"aspects":[{"claim_count":20,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":18,"title":"Primary endpoint: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)"},{"claim_count":20,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":16,"title":"Primary endpoint: Overall Survival (OS)"},{"claim_count":15,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":13,"title":"Secondary endpoints"},{"claim_count":25,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":14,"title":"Population and setting"},{"claim_count":9,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":7,"title":"The comparison"},{"claim_count":30,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":21,"title":"Safety and tolerability"},{"claim_count":13,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":8,"title":"Design and conduct"},{"claim_count":51,"coverage":"discussed","id":"A1","source_count":37,"title":"Clinical positioning and strength of endorsement"},{"claim_count":12,"coverage":"discussed","id":"A2","source_count":9,"title":"Patient selection, subgroup uncertainty and ADC sequencing"},{"claim_count":20,"coverage":"discussed","id":"A3","source_count":12,"title":"Authorization, funding, access and clinical-trial discussion"},{"claim_count":25,"coverage":"discussed","id":"A4","source_count":12,"title":"Targeted-delivery rationale and earlier disease-specific sac-TMT evidence"}],"counts":{"beyond_population_findings":7,"beyond_population_statements":64,"cited_clinicians":22,"cited_clinicians_by_role":{"physician":3,"physician, Gynecologic oncology":1,"physician, Medical oncology":9,"physician, Pathology":1,"physician, Surgical oncology":8},"cited_physicians":22,"cited_sources":72,"claims_by_expression_type":{"comparison":13,"experience":4,"interpretation":62,"opinion":44,"primary_context":5,"question":11,"restatement":57,"uncertainty":12,"unspecified":14},"claims_by_kind":{"interpretation":2,"protocol_statement":1,"publication_statement":4,"source_observation":215},"clinician_statements":66,"evidence_units":166,"findings":6,"organisational_accounts":21,"people_cited":35,"people_identity_verified":26,"people_total":37,"screened_sources":160,"verified_claims":222},"findings_index":[{"cited_clinicians":5,"id":"F1","structure":{"claims":14,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":2,"views":10},"limitations":2,"links":{"context":1,"support":14},"ma_question":true,"named_voices":8,"passages":9,"sources":9,"sources_by_kind":{"commentary":8,"media":1}},"title":"One interview calls sac-TMT a current standard of care; clinical accounts qualify broad adoption"},{"cited_clinicians":5,"id":"F2","structure":{"claims":18,"claims_by_group":{"comparisons":3,"experience":2,"questions":0,"restated":3,"views":10},"limitations":2,"links":{"context":6,"support":23},"ma_question":true,"named_voices":6,"passages":21,"sources":13,"sources_by_kind":{"commentary":10,"media":2,"publication":1}},"title":"Clinical accounts weigh survival gains against greater toxicity; one episode links manageability to prevention"},{"cited_clinicians":2,"id":"F3","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":0,"questions":6,"restated":0,"views":3},"limitations":3,"links":{"context":0,"support":10},"ma_question":true,"named_voices":3,"passages":7,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Clinical accounts ask who should receive sac-TMT and how to sequence it with other ADCs"},{"cited_clinicians":5,"id":"F4","structure":{"claims":13,"claims_by_group":{"comparisons":2,"experience":0,"questions":2,"restated":5,"views":4},"limitations":3,"links":{"context":1,"support":15},"ma_question":true,"named_voices":6,"passages":11,"sources":9,"sources_by_kind":{"commentary":7,"media":2}},"title":"One speaker defends the chemotherapy comparator; other accounts stress evidence maturity"},{"cited_clinicians":0,"id":"F5","structure":{"claims":15,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":6,"views":8},"limitations":3,"links":{"context":3,"support":16},"ma_question":true,"named_voices":3,"passages":12,"sources":11,"sources_by_kind":{"commentary":7,"media":4}},"title":"Accounts distinguish clinical enthusiasm from authorization and access"},{"cited_clinicians":3,"id":"F6","structure":{"claims":14,"claims_by_group":{"comparisons":2,"experience":0,"questions":4,"restated":5,"views":3},"limitations":3,"links":{"context":6,"support":16},"ma_question":true,"named_voices":3,"passages":12,"sources":6,"sources_by_kind":{"commentary":1,"media":5}},"title":"Speakers explain sac-TMT through targeted-delivery analogies; one report cautions against cure expectations"}],"open_question":{"basis":"From finding F1 (14 statements from 8 speakers in 9 sources)","cited_claim_ids":["claim-a0c4eb5c3cbfbda197f2","claim-53e0bf49166f597d0707","claim-7a2e8c0afb08d59074ac","claim-ebfb7d76cbb2bfb75970","claim-296369f4e77a0803f3a2","claim-22f0615e223f61a8ecd1","claim-2eb9e7d30cca4836689e","claim-55df0f37e1127644cf1a","claim-e759f1b40dce0fb57401","claim-209721bc02736bce8d27","claim-716dce9a9fe9a7c28ce3","claim-c40748e0f3f15fddaac7","claim-1742620903a0c5763ddc","claim-e02e6f939517f187ac7d"],"finding_ids":["F1"],"question":"What do clinicians say they still need to see on longer-term safety, biomarker analyses, subgroup results and treatment sequencing before broadly adopting sacituzumab tirumotecan for recurrent endometrial cancer after platinum chemotherapy and immunotherapy?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One interview declares a current standard; other accounts qualify broad adoption"},{"id":"section-2","level":2,"title":"Clinical accounts balance benefit with toxicity; one episode makes prevention central to manageability"},{"id":"section-3","level":2,"title":"Clinical accounts leave patient selection and ADC sequencing unresolved"},{"id":"section-4","level":2,"title":"One speaker defends the control arm; accounts distinguish trial delivery from evidence maturity"},{"id":"section-5","level":2,"title":"Accounts separate clinical positioning from authorization, funding and referral"},{"id":"section-6","level":2,"title":"Speakers use targeted-delivery explanations; one report rejects a cure interpretation"},{"id":"section-7","level":2,"title":"Beyond the trial population"},{"id":"section-8","level":3,"title":"Clinicians question routine checkpoint reuse but retain selective exceptions"},{"id":"section-9","level":3,"title":"One speaker requires diagnostic confirmation; speakers consider local control before systemic replacement"},{"id":"section-10","level":3,"title":"Speakers make fitness, work-up and patient goals central to the next treatment"},{"id":"section-11","level":3,"title":"One educational discussion asks practices to build ADC safety capability"},{"id":"section-12","level":3,"title":"An ovarian-cancer episode links sac-TMT observations to proposed phase III development after dose optimization"},{"id":"section-13","level":2,"title":"Scope and coverage"},{"id":"section-14","level":3,"title":"One speaker values a research pathway after the chemotherapy arm"},{"id":"section-15","level":3,"title":"Public accounts interpret development potential and commercial significance"},{"id":"section-16","level":2,"title":"Scope and coverage of the sources reviewed"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":3},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1}],"id":"T1","label":"Primary endpoint: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1}],"id":"T2","label":"Primary endpoint: Overall Survival (OS)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":3},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":2}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F4","shared_claims":4}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":15},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F4","shared_claims":7},{"id":"F5","shared_claims":2}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-12T03:56:03.142876Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-12T04:13:35Z","record_hash":"2cae0c005cfa49ce73bee7a958782e38bc2b37eab52db7624db9b8ce1c58e4b7","release_hash":"eac21b48fa95ee6198488c48be4baa4b54cfb21e4611c4917bb1f6ad67d3e268","report_id":"erudio-nct06132958","run_id":"941a196a-0115-4b0d-8cf0-a22672b2e910","schema_version":"5.0","slug":"trofuse-005-nct06132958","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A speaker described in the sources as presenting TroFuse-005 endorses routine sac-TMT use today, citing survival benefit they consider clinically meaningful, but a medical oncologist wants longer-term safety evidence before wider use. That caution reflects increased severe treatment-related toxicity. Conflicting authorization accounts leave current approval and funded access unclear.","examples":[{"claim_id":"claim-ebfb7d76cbb2bfb75970","finding_id":"F1","identity_check":"staff_page","month":"2026-10","region":"ex-US","role":"Medical oncologist","source_type":"linkedin_post","statement":"considers longer-term safety, biomarker analyses and optimal treatment sequencing essential before widespread adoption of sacituzumab tirumotecan in this setting."}],"meta_description":"160 sources screened · 222 verified statements (66 from clinicians verified by NPI or staff page) from 72 sources · 6 findings. Updated Nov 12, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-12T04:13:35Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-11-12T19:00:00Z","kind":"routine","summary":"A sentence that said more than its speaker's words was removed."},{"affected_ids":[],"date":"2026-11-12T19:00:00Z","kind":"routine","summary":"The trial's name is spelled as its investigators write it, “TroFuse-005” (NCT06132958), outside quotations (was “Trofuce”)."},{"affected_ids":[],"date":"2026-11-12T16:19:35Z","kind":"routine","summary":"Corrected to match the delivered report: the question clinicians left open; per-finding counts; the limitations; the examples from the report; the abstract, which no longer repeats the open question; the report description."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":160},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Not yet captured in this edition: a view on treatment history and unmet need when considering antibody–drug conjugates after chemotherapy and immunotherapy; a view on checkpoint switching versus adding lenvatinib after progression on immunotherapy in endometrial cancer; a remark on an inference explicitly qualified as an assumption without supporting data; a view on prioritizing a treatment-comparison trial in previously treated recurrent or advanced endometrial cancer.","Discussion that does not name the trial may be missing from this edition.","5 matching sources (3 YouTube videos, 2 X threads) could not be read and are not included.","1 passage in 1 source used in this report was not fully assessed for clinician views, so a view there may be missing from this edition.","333 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 5 sources about other trials or topics are not included.","The sources reviewed for this edition are not representative of all HCPs or all public discussion, and source totals cannot be interpreted as numbers of independent clinicians.","Two social threads and three video transcripts were unavailable. Other passages could not be described reliably or fully: the origin of reported evidence was unclear in two, while additional material left safety qualifications, prior-treatment distinctions, an account’s prioritization or an explicit evidence limitation incompletely represented. Another passage was not fully assessed. These gaps may obscure minority positions and practical qualifications.","The treatment-choice discussions are not exhaustive. Absence of an option or exception from this report does not show that a speaker rejected it or failed to discuss it.","Several passages cannot be assigned to a named speaker. A guest list, program description, profile or research identity does not establish who spoke those words.","Public accounts, organizations, investor-oriented commentary and an episode containing AI-generated content contribute some views; their inclusion does not establish clinical expertise or independent clinical endorsement.","Earlier design and access discussions, May 2026 announcements and October–November 2026 detailed-result commentary concern different information states. Dates alone do not demonstrate a change of mind.","Interim follow-up, unresolved subgroup and biomarker questions, limited quality-of-life detail and absent comparative sequencing evidence constrain implementation interpretations.","Safety accounts distinguish overall adverse events, treatment-related adverse events, serious events, discontinuation and treatment-related deaths; these measures should not be merged.","No exact sacituzumab tirumotecan label was available, and jurisdictional authorization descriptions conflict, so the report does not determine current approval or reimbursed access.","Small retrospective rechallenge series, individual clinical experiences and subsequent-trial anecdotes do not provide direct comparative evidence against sac-TMT.","Source-described roles and trial involvement are not independently confirmed professional appointments or proof of an external, independent assessment. Professional associations also do not establish current employment.","The ovarian-cancer educational account is development context only. Its activity observations and corrected description of a path to Phase III are not endometrial-cancer TroFuse-005 results. Its full toxicity and supportive-care discussion is not captured here, so the account should not be used as a complete benefit–risk appraisal or evidence of comparative tolerability."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":4,"linkedin_post":8,"other":0,"podcast":9,"publication":1,"registry":1,"regulatory":0,"x_thread":42,"x_video":0,"youtube":7},"by_evidence_role":{"commentary":70,"context":1,"methods":1},"count":72,"evidence_window":{"end":"2026-11-05","start":"2024-05-01"},"retrieval_snapshot":"2026-11-12T02:20:52.294112Z","timeline":[{"count":1,"week":"2024-W18"},{"count":1,"week":"2024-W37"},{"count":1,"week":"2024-W40"},{"count":1,"week":"2025-W11"},{"count":1,"week":"2025-W17"},{"count":1,"week":"2026-W05"},{"count":1,"week":"2026-W12"},{"count":1,"week":"2026-W14"},{"count":11,"week":"2026-W21"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W29"},{"count":1,"week":"2026-W32"},{"count":2,"week":"2026-W40"},{"count":1,"week":"2026-W43"},{"count":39,"week":"2026-W44"},{"count":6,"week":"2026-W45"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT06132958:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06132958:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42933460","quote_policy":"short_quote_link_out"},{"id":"openfda:55889588-c5f1-d9bc-e063-6294a90a5791:20261103","quote_policy":"short_quote_link_out"},{"id":"openfda:e4be6cbf-72b9-4f7f-9b1b-459b2d35961a:20260909","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-42han5exrxyrgdsbwosrp7sy-3mmcilx4znh2l","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-47nm5qperrpmcqdmzxt3qgec-3mz3nqr2fdk25","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4axwsf5hlk2omckvoolonim6-3myseoav6a7o2","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4dltatq7ihso6qvyyodpacqb-3mm54bub5bc2a","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4dltatq7ihso6qvyyodpacqb-3mm5gyqwa722y","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4dltatq7ihso6qvyyodpacqb-3mmqpotoegc2f","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-5cawaaxt7xfm5shgleleufdz-3myssg4dwjj2q","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-5xpa74q7sm6ajcvoc5lxltez-3mys6mcnkns2j","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-cg5bjyxf74w3vg7lo4zqwpzg-3mys745xuva2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-dtg2oeh4jj3lmbcxyxl6nm34-3mm53hxoxyg2i","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kwntu4mgap2otpkyzq5bchim-3mys2ojwih32n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-nojwodfxv6vgcz7y2s5tdwnl-3mmcp2gx5lm22","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ryo5z53ggbjijxq7nd6ftqjx-3mywnfkxte22y","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-v2bbfxjs2fopw6y76ibai2cd-3mysdcl5oc32l","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-vlbpdban632brzgecx2wjol2-3mmylrb3wze2y","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zepuoisn2ufhmaqjqaljaqki-3mmbponuqis23","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3myrig6z7ml27","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7462109815889195008","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7462123079331135488","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7520058234964082688","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7520559787470782464","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7520751718658306048","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7520793788383145984","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7520795154904178688","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7520869814567878657","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7522624573276794880","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7523176580995645441","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:348898","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:367504","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:6bcd30","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:78237d","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:7fdfb3","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:8c3c45","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:c1a954","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:ca9a93","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:fa4178","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1776312842955960540:9778c085-782c-424e-bb5f-90379e530d81","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835310268605223179:6cfd6bbb-7cd3-4184-b21c-7b5e778842d4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056325583689195741:7c597022-f1ae-4600-a550-2789de1a7e68","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056328849042886663:0db4bf40-1047-43ba-8d03-b8e23823d180","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056336646681846056:5d95f1d4-5119-40e4-893a-ed860e3a10dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056341098247709082:c641e72a-b5dd-4f7b-933d-08bbb5beb125","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056375014472184027:dad4867e-1e5d-48e0-90cf-62eded7900a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056613641869283490:87be3206-a2cf-416d-84f6-47c59ad4ef03","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056785741712175342:87753171-0dfa-4d03-8bb8-6d0cfbce9211","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056922349501665757:ad00e465-ad4f-4e6a-bbee-8c223fc7b015","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057329888491958376:8aa61e31-5bec-420c-98c4-4411bde06628","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057710996890980799:f892c69d-fd71-4295-9179-b22a7454d527","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057744237387551134:6bffda82-2076-4992-a9b0-d2913ce4a280","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057774220013142120:3fb304ef-89aa-43cc-99c5-e951d876a421","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2078052877939904991:c9ae01fb-c0bc-42c0-9bca-37191777f7b2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2084776463241183542:22c0c6f3-95c4-4f5b-8e31-737d45c3982b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102550129924624622:462e9657-e054-461b-bbae-f711f6b23639","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102775635102007809:022c5c54-563f-4884-9041-89ca62bdef05","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102813261150532034:13a5a12d-9204-4ca9-bf67-2c16c54dc10c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104576990355292208:37aa925b-12a5-455b-bd26-709c80675c22","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105287745358721037:5db7d549-2e36-4e61-a51c-04fa8eb46795","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105462841733943807:663ccded-e0b6-42ad-9d9b-824cd7682f9b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2106042283623879003:fd412b8c-4325-477c-a32b-f90fa4009f07","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107882773721555076:c6e357a6-bd2b-4d8c-b790-a8534703afa5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108492836975124671:41be4c45-1c37-4dac-bf79-6f5dfa374d17","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108742921398964674:fbdfd369-9224-4f1a-9f79-7b4d608a6384","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110081409297650066:9abfe219-72ee-4de6-93fe-5501b9fe0b67","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112346104956428458:9ab0e639-a876-4880-9dbe-1fe1dc63c4d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112636565541298324:32189c8d-869e-4698-ba18-e5c1bf96e1fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112654409658187912:9c7446c6-974f-4afc-96cf-65ae1498e55c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113000120941965610:bc5411a9-e33b-457b-b1b9-30c0db3efe15","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113189421252235385:90ada5ad-e848-4b96-ac29-930350d0e351","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113261592829640762:428fc516-2c4e-4909-b55d-02951e575ed6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113464721567523254:3c0a7b85-64f6-4254-99a6-8cffb35f62ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113566049102889208:a5ce3b9c-db5a-4826-9ccd-0b19918e07b2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113573590545412264:75a8d7a5-291d-4718-8b0a-8a204b8f809e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113950495777714412:caaf546b-846c-4ce4-9bb4-da8cc7d370eb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114370585606410361:4c99d9a0-d236-48e0-919a-761e9f3c4dd7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114510878477287429:9598b1fc-3775-4bb3-b811-377813daf38d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114512764345692616:6cd2dc77-30a6-4276-abcd-bfb1541ff0e9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114513737705246939:202e14d1-dcc3-4807-875f-3e89fb2d1173","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114564508484284774:579ca116-d30c-4f3f-ab52-33bb776873ab","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114587674837188971:a6fb4f15-3107-4a79-8b00-02c637bd226f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114602853444862162:fa00096c-5e62-432b-8526-2383845cec53","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114661931063668959:69fba42a-bc9b-45ed-a0f9-7ac1f6e99e69","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114711144644399433:cbe36daf-e203-4316-b6b6-3d7e7b194bff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114711310571094293:7ed81738-fffa-41fd-afb7-8d0ca617e56e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114746335999975781:51906f63-4fcd-4369-b003-c0f8d7394e8a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114748486633799911:15c4f4cc-dd40-4a22-816a-29347ba329e1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114749123291132124:b16f7635-829e-4739-8074-4a0bfb796865","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114761181395095735:941248af-774c-478a-b3d0-5c693f9634be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114761855986266407:a060e145-6c85-42ee-9f6d-5768d8dd32e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114762086408413550:d083d46b-ef09-4ce2-834b-786d40bfb50f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114763576603005209:0575a20e-f95c-4242-b365-83536f09eda3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114764104090947837:87cc9add-81b2-4534-8c1d-aef8f501ea14","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114765188184367538:a73f7426-3a94-4857-b08a-636823616639","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114766113435418793:f5c4ae31-e79e-410b-9a6a-13bf7ab833d3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114766814890897650:8dd6c2ad-eea9-479f-b050-812e98f7b2e0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114767215534952778:1293cef3-466e-488d-aa74-dff17d9c04d4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114770001034920060:ecf329d5-aedf-4510-805f-5257cb9b6b35","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114770187765600479:83bb9fda-3ab3-4241-8369-ff58e831b0a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114779404262097350:03a99574-6a6e-4841-9fb9-fd1dc54869d0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114780349959901580:7a8a1994-98e7-4ff8-88cd-63972ccb047e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114781351383879697:31bc0786-bc48-4910-9e59-2fce0beb2f20","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114783018703307102:584a866b-bdac-4189-8e4a-18dfcbdf2aa8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114784376752107877:71f967aa-627f-4713-8f30-98da20c5dbbc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114784468812591121:90f21ebf-4db0-4925-9ab7-3dc864fd9b04","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114786786383642654:dd484e2e-701d-4675-a511-a77000480677","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114790317283295467:10f8f71e-94e0-4e21-b102-debb08943884","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114801808753258532:6c143794-3c39-437f-adbf-24f877c68c30","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114805010034770376:7aac34f1-7e02-412b-83ad-69364b763d4d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114817343725490553:bd0016d6-d910-4335-93fb-d08ea5175213","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114820537679565169:c6817eda-a343-4ab4-898b-05b6fd20c1ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114823133148365240:faba9ff1-6c3c-4652-b2e1-619445a733f9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114834839773778051:de3bb5b9-18b9-493a-b495-617dee889205","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114836131946590705:731a55dc-81c6-4dae-9842-4b5ae29a03ef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114843115206922746:ae2a2d0a-4386-4f98-a5dc-e05b38dc7a95","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114861826454290738:7823c4b6-2927-456c-861e-d08604349a38","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114863573188890789:6eaf8e7f-7ff8-4254-990d-89b4f09178bf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114884925564354784:662898a9-57f4-467d-92dc-c9934fc0333b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115000795800228026:e2683ec5-32ca-449e-929b-22425691c440","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115029590183653859:92770ac9-a8fd-4bc5-af81-7f05a7992704","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115035529318117542:19443d07-be1c-4af0-817d-ef2501955b3b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115066316315062673:3ae1381c-3efd-416f-858c-8343b57a4afe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115071892486795404:d7eba8ce-2854-48d7-8de0-741ec5055493","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115071977077473529:ce766df2-994c-4eef-b94f-0f9746ab817d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115072110615761223:9c83b60e-0e1c-4ec4-8c19-f4384ff88720","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115072299200139705:66ef4a86-d8d5-4188-9bac-abd8c8730c6a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115072506587418751:2e4be50e-5a89-44b8-94dd-b6f811f79c51","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115081081384821141:6d7fca09-3f1c-406b-baf8-8a8cd06fee03","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115081084937638271:d160ae0c-b6c4-4d55-97b3-e6309046d488","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115089182762684855:76655526-1968-4124-b23c-3a3df6b85ef4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115104373915418739:976dd298-45ca-4e7f-b684-959e038d9866","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115104646113136857:908649f5-a762-4691-80b0-4ac51140af3a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115104788174217507:31537845-c2ec-4e10-b847-66492a53b663","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115105147122831535:720cc2c0-0706-4303-aa70-6a6b383c1ca4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115115309531041990:81e86c62-6f04-481f-880f-090167512a42","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115121854436327897:f8ce5caa-4c7f-49b3-8eb0-249029a92e51","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115150793229717998:4fc237d3-18e2-4ae6-a7d9-f4631e63bc85","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115159805891387429:91c8da50-6449-45bd-ada1-aff4ff24037d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115182312162029961:019ab8f4-37c9-4b66-9116-fda9ca0b3894","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115383080479347006:7a8b19c6-5952-457a-b083-30a6b79c8494","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115727964000170399:0c034e23-def1-4406-bf6f-3caf2beedb90","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115773616054788501:c9441c02-1b1d-47bc-8c46-f77fb83d32af","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115777927925096882:bd676021-8872-4fcf-a90a-a550da26f080","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115783318025179347:272b118d-be82-4811-bbf4-0fc5dd1125dd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115807715083616762:50a9ed23-c6b5-4bc4-a6dd-5e9c0e1b9438","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115857678723395858:27fbf2f5-4db8-4f95-bdfa-21314f401614","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115892732128264515:0f9e221b-3f36-41f3-a0fa-61cd24d58d37","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116127106270712062:09344a93-d25a-4cfb-9f6f-be74a823da11","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116802481174778132:e2307dd2-c1f5-4a17-84e3-34835394242e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2117268847434645892:a44ed925-c6f4-4ae1-8185-ec7ec51fe945","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2117362496311083045:7991e477-9018-4772-9112-2b136dcf1aa7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2117464949299851528:a3e0f2cc-088d-471b-b1b6-aae4ba278685","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2117635825328406644:042e8110-9c2b-406f-8cf5-8365a01a6783","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2117772366050943264:55b5e0cc-0384-4e11-a307-e2074170122d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2117957534707265797:35e6b62f-45f9-4cf1-8351-bac3c4bd8160","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:75ejv0ZH4JY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:A-anN2iA9u4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:PaOpLnI8Qoc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:WHBOY6HIDz8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:jxTAETMVN6M","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:lTVgjmed6zE","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:xFvfhSiC97g","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":17,"linkedin_post":10,"other":0,"podcast":9,"publication":0,"registry":0,"regulatory":0,"x_thread":117,"x_video":0,"youtube":7},"by_evidence_role":{"commentary":160},"count":160,"evidence_window":{"end":"2026-11-05","start":"2024-04-05"},"retrieval_snapshot":"2026-11-12T02:20:55.645961Z","timeline":[{"count":1,"week":"2024-W14"},{"count":1,"week":"2024-W18"},{"count":1,"week":"2024-W37"},{"count":1,"week":"2024-W40"},{"count":1,"week":"2025-W11"},{"count":1,"week":"2025-W17"},{"count":1,"week":"2026-W05"},{"count":1,"week":"2026-W12"},{"count":1,"week":"2026-W14"},{"count":22,"week":"2026-W21"},{"count":3,"week":"2026-W22"},{"count":1,"week":"2026-W29"},{"count":1,"week":"2026-W32"},{"count":3,"week":"2026-W39"},{"count":4,"week":"2026-W40"},{"count":3,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":12,"week":"2026-W43"},{"count":91,"week":"2026-W44"},{"count":10,"week":"2026-W45"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":9,"linkedin_post":19,"other":0,"podcast":54,"publication":4,"registry":1,"regulatory":0,"x_thread":67,"x_video":0,"youtube":68}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":[{"label":"ESMO Congress 2026","slug":"esmo26","sources":26}],"drugs":[{"reason":"Unmapped registry intervention: sacituzumab tirumotecan","status":"unmapped"},{"brand_names":["Adriamycin","Rubex"],"label":"doxorubicin","slug":"doxorubicin"},{"brand_names":["Taxol"],"label":"paclitaxel","slug":"paclitaxel"},{"brand_names":["Abraxane"],"label":"nab-paclitaxel","slug":"nab-paclitaxel"},{"reason":"Unmapped registry intervention: rescue medications","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Endometrial cancer","slug":"endometrial-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"TroFuse-005","aliases":["TroFuse-005","Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)"],"brief_title":"Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","collaborators":["European Network of Gynaecological Oncological Trial Groups (ENGOT)","GOG Foundation"],"conditions":["Endometrial Cancer"],"display_condition":"endometrial cancer after platinum-based chemotherapy and immunotherapy","display_interventions":[["sacituzumab tirumotecan"]],"enrollment":{"count":710,"type":"ESTIMATED"},"interventions":[{"name":"Sacituzumab tirumotecan","synonyms":["SKB264 MK-2870"],"type":"BIOLOGICAL"},{"name":"Doxorubicin","synonyms":["ADRIAMYCIN®"],"type":"DRUG"},{"name":"Paclitaxel","synonyms":["TAXOL®"],"type":"DRUG"},{"name":"Nab-paclitaxel","synonyms":["Abraxane"],"type":"DRUG"},{"name":"Rescue medications","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06132958","official_title":"A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)","other_names":[{"kind":"also","name":"ENGOT-en23"},{"kind":"also","name":"GOG-3095"}],"overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-01-10","type":"ESTIMATED"},"primary_endpoints":[{"description":"PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on BICR or death due to any cause, whichever occurs first.","measure":"Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to approximately 27 months"},{"description":"OS is defined as the time from randomization to death due to any cause.","measure":"Overall Survival (OS)","timeFrame":"Up to approximately 48 months"}],"registered_date":{"date":"2023-11-15","type":"ACTUAL"},"registry_last_updated":"2026-08-28","registry_url":"https://clinicaltrials.gov/study/NCT06132958","short_name":"TroFuse-005","short_name_basis":"registry_acronym","sponsor":"Merck Sharp & Dohme LLC","start_date":{"date":"2023-12-06","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"2870-005","type":"sponsor_study_id"},{"domain":"EU CT","id":"2023-504816-14-00","type":"registry"},{"domain":"UTN","id":"U1111-1288-7581","type":"registry"},{"domain":"Japan Registry of Clinical Trials (jRCT)","id":"jRCT2031240041","type":"registry"}],"study_type":"INTERVENTIONAL"}}}